Product/Composition:- | Empagliflozin Tablets |
---|---|
Strength:- | 10 mg, 25 mg |
Form:- | Tablets |
Reference Brands:- | Jardiance(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Empagliflozin, an SGLT2 inhibitor, blocks glucose reabsorption in kidneys, promoting urinary glucose excretion. This lowers blood sugar in type 2 diabetes. Benefits include improved glycemic control, weight loss, blood pressure reduction, and cardiovascular risk reduction, with a low risk of hypoglycemia.
Empagliflozin is a selective SGLT2 inhibitor approved for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. In the USA, the FDA approved Jardiance (10 mg, 25 mg) in 2014. In the EU, it is authorized by the EMA under centralized procedure. It is often prescribed as monotherapy or in combination with metformin or insulin. Empagliflozin improves glycemic control and reduces cardiovascular risks. Regular renal monitoring is advised. Pharmatradz.com connects global buyers and suppliers with licensed manufacturers of Empagliflozin, ensuring regulatory-compliant sourcing for B2B needs in both regulated and semi-regulated markets.